Rejuvenating immunity: “anti-aging drug today” eight years later

Mikhail V. Blagosklonny

doi:10.18632/oncotarget.3740

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Rejuvenating immunity: “anti-aging drug today” eight years later

Mikhail V. Blagosklonny _

PDF | HTML | How to cite

Oncotarget. 2015; 6:19405-19412. https://doi.org/10.18632/oncotarget.3740

Metrics: PDF 3345 views | HTML 6269 views | ?

Abstract

Mikhail V. Blagosklonny1

1 Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA

Correspondence to:

Mikhail V. Blagosklonny, email:

Keywords: mTOR, TOR, gerosuppression, rapalogs, lifespan, longevity, diseases

Received: February 16, 2015 Accepted: March 28, 2015 Published: March 31, 2015

Abstract

The 2014 year ended with celebration: Everolimus, a rapamycin analog, was shown to improve immunity in old humans, heralding ‘a turning point’ in research and new era in human quest for immortality. Yet, this turning point was predicted a decade ago. But what will cause human death, when aging will be abolished?

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3740

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Rejuvenating immunity: “anti-aging drug today” eight years later

Abstract